The Relationship Between Glycated Hemoglobin and Time in Range in a Pediatric Population.

IF 5.7 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes technology & therapeutics Pub Date : 2024-05-01 Epub Date: 2024-01-04 DOI:10.1089/dia.2023.0482

Mathilde Vandenbempt, Hanne Matheussen, Sara Charleer, Anne Rochtus, Kristina Casteels

{"title":"The Relationship Between Glycated Hemoglobin and Time in Range in a Pediatric Population.","authors":"Mathilde Vandenbempt, Hanne Matheussen, Sara Charleer, Anne Rochtus, Kristina Casteels","doi":"10.1089/dia.2023.0482","DOIUrl":null,"url":null,"abstract":"In adults with type 1 diabetes (T1D), time in range (TIR) [70-180 mg/dL] has been proposed as an additional metric besides glycated hemoglobin (HbA1c). This retrospective monocentric cohort study determined the correlation between HbA1c and TIR during the 2, 4, and 12 weeks (TIR2w, TIR4w, and TIR12w) before consultation in a pediatric T1D population. A total of 168 children with T1D were included. Continuous glucose monitoring data, HbA1c, and demographic variables were collected. We found strong linear correlations between HbA1c and TIR2w (R = -0.571), HbA1c and TIR4w (R = -0.603), and between HbA1c and TIR12w (R = -0.624). A strong correlation exists between TIR2w and TIR12w, HbA1c and time above range (TAR), and between TIR and TAR at different time points. In conclusion, a strong correlation was found between HbA1c and TIR, making TIR a potentially complementary metric to HbA1c. TIR2w seems a viable alternative to TIR12w. TAR also seems promising in assessing glycemic control.","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":null,"pages":null},"PeriodicalIF":5.7000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes technology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/dia.2023.0482","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

In adults with type 1 diabetes (T1D), time in range (TIR) [70-180 mg/dL] has been proposed as an additional metric besides glycated hemoglobin (HbA1c). This retrospective monocentric cohort study determined the correlation between HbA1c and TIR during the 2, 4, and 12 weeks (TIR_2w, TIR_4w, and TIR_12w) before consultation in a pediatric T1D population. A total of 168 children with T1D were included. Continuous glucose monitoring data, HbA1c, and demographic variables were collected. We found strong linear correlations between HbA1c and TIR_2w (R = -0.571), HbA1c and TIR_4w (R = -0.603), and between HbA1c and TIR_12w (R = -0.624). A strong correlation exists between TIR_2w and TIR_12w, HbA1c and time above range (TAR), and between TIR and TAR at different time points. In conclusion, a strong correlation was found between HbA1c and TIR, making TIR a potentially complementary metric to HbA1c. TIR_2w seems a viable alternative to TIR_12w. TAR also seems promising in assessing glycemic control.

查看原文本刊更多论文

儿科人群中 HbA1c 与时间范围之间的关系。

在 1 型糖尿病（T1D）成人患者中，除 HbA1c 外，还有人建议将时间在范围内（TIR）[70-180 mg/dl]作为额外指标。这项回顾性单中心队列研究确定了儿科 T1D 患者就诊前 2 周、4 周和 12 周（TIR2w、TIR4w 和 TIR12w）内 HbA1c 与 TIR 之间的相关性。共纳入了 168 名 T1D 儿童。我们收集了连续血糖监测数据、HbA1c 和人口统计学变量。我们发现 HbA1c 与 TIR2w（R = -0.571）、TIR4w（R = -0.603）和 TIR12w（R = -0.624）之间存在很强的线性相关。不同时间点的 TIR2w 和 TIR12w、HbA1c 和超范围时间（TAR）以及 TIR 和 TAR 之间存在很强的相关性。总之，HbA1c 和 TIR 之间存在很强的相关性，因此 TIR 有可能成为 HbA1c 的补充指标。TIR2w 似乎是 TIR12w 的可行替代方案。TAR 在评估血糖控制方面也很有前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes technology & therapeutics 医学-内分泌学与代谢

CiteScore

10.60

自引率

14.80%

发文量

145

审稿时长

3-8 weeks

期刊介绍： Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and each issue highlights new pharmacological and device developments to optimize patient care.